isosteviol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alagal, RI; Alfaris, NA; Aljabryn, DH; Alshammari, GM; Altamimi, JZ; Yahya, MA | 1 |
| Han, T; Hu, TT; Liu, XY; Tan, W; Tang, SG; Yang, YY; Ye, JM | 1 |
2 other study(ies) available for isosteviol and Alloxan Diabetes
| Article | Year |
|---|---|
Isosteviol attenuates streptozotocin-mediated diabetic nephropathy in rats by upregulating and stimulating adenosine monophosphate-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Insulins; Male; NF-E2-Related Factor 2; NF-kappa B; Nuclear Proteins; Rats; Streptozocin | 2023 |
Isosteviol ameliorates diabetic cardiomyopathy in rats by inhibiting ERK and NF-κB signaling pathways.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diterpenes, Kaurane; Down-Regulation; Heart; Hypoglycemic Agents; Male; MAP Kinase Signaling System; Myocardium; NF-kappa B; Rats; Rats, Wistar; Signal Transduction; Streptozocin | 2018 |